Tirzepatide is typically started at a dose of 2.5 mg, administered once a week as a subcutaneous injection
Warning signs include: Cloudiness or turbidity in the solution Visible particles floating in the liquid Color changes or discoloration Any signs of freezing If any of these visual changes are present, the medication should not be used and should be discarded according to local guidelines for pharmaceutical waste
Additional areas of active investigation include the peptide's potential effects on bone healing, where studies have reported accelerated fracture consolidation in animal models
PubMed Central, Jakubowski, Hieronim
#Ophthalmology #CataractSurgery #RefractiveSurgery #GLP1 #Semaglutide #Mounjaro #EyeCare #Diabetes M Saba Haddadian We saw shift in patients above 1 month use of this medication
Moreover, alterations in the activity or concentration of cystathionine -synthase and cystathionine -lyase have been associated with various pathological conditions and diseases, including diabetes, cancer, AIDS, neurodegenerative disorders, and liver diseases [29, 30, 31]
